Financings Of The Fortnight: Market Lessons From The Contrave Complete Response Letter
This article was originally published in The Pink Sheet Daily
Plus news on financial transactions by Seattle Genetics, Nektar, Pharmasset and Pacira.
You may also be interested in...
Nektar Therapeutics Inc. will launch the Phase III BEACON trial by the end of this year for its NKTR-102, a next-generation version of the now generic topoisomerase 1 inhibitor irinotecan (Pfizer Inc.’s Camptosar). The trial, in pretreated metastatic breast cancer patients, will have a raft of endpoints designed to help gain acceptance in the crowded field.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.